C(O)[C@@H]([C@@H](CO)O)O.[CH3:9][N:10]1[C@@H:15]2[C@@H:16]3[O:18][C@@H:17]3[C@H:11]1[CH2:12][CH:13]([O:19][C:20]([C@@H:22]([C:25]1[CH:30]=[CH:29][CH:28]=[CH:27][CH:26]=1)[CH2:23][OH:24])=[O:21])[CH2:14]2>>[CH3:9][N:10]1[C@@H:15]2[C@@H:16]3[O:18][C@H:17]3[C@H:11]1[CH2:12][C@@H:13]([O:19][C:20]([C@@H:22]([C:25]1[CH:26]=[CH:27][CH:28]=[CH:29][CH:30]=1)[CH2:23][OH:24])=[O:21])[CH2:14]2A casting solution was prepared containing 4.0% CMC and 1.0% erythritol. A 10.0 mg aliquot of scopolamine HCl was dissolved into 50 g of the casting solution thereby yielding a scopolamine HCl concentration of 200 μg/g of the casting solution. A 1.2543 g amount of the casting solution containing the drug was equally divided between the three wells of the sample BP strip. PAM® was employed as a release agent. After 45 minutes in the IR drying tunnel the recovered weight was 105% of the theoretical NVS. The resulting films easily released from the casting well and were clear and flexible. Each film swatch averaged 22 mg and contained 8.4 μg of scopolamine HCl.